A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
M15-531
Phase 1 other active
Quick answer
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS) for Myelodysplastic Syndromes (MDS) is a Phase 1 program (other) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Myelodysplastic Syndromes (MDS)
- Phase
- Phase 1
- Modality
- other
- Status
- active